Iterum Therapeutics (ITRMF) AI Stock Analysis

• Market Cap: $591.75K
• Dividend Yield: N/A
• Average Volume (3M): 813.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.04
• Revenue Growth: N/A
• EPS Growth: 62.61%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 52,835,200
• 10 Day Avg. Volume: 1,119,323
• 30 Day Avg. Volume: 813,222
• PEG Ratio: 0.02
• Price to Book (P/B): -8.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.30
• Enterprise Value/Market Cap: 39.42
• Enterprise Value/Revenue: 59.82
• Enterprise Value/Gross Profit: -34.92
• Enterprise Value/Ebitda: -1.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.31
• Revenue Forecast (FY): $9.38M

• Rating: 43 Neutral
• Price Target: $0.31 ▼(-8.53% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.

Positive Factors

Patent expansion (China & Mexico)

Extended patents in China and Mexico through 2039–2041 materially lengthen market exclusivity in key international jurisdictions. This strengthens long-term commercial upside, supports pricing power versus generics, and enhances licensing or partnering optionality across global markets.

Negative Factors

Negative shareholders' equity and elevated leverage

Negative equity and debt that exceeds assets constrain financial flexibility and increase refinancing and dilution risk. This capital-structure weakness can limit investment in commercial scale-up or R&D and raises vulnerability to adverse funding conditions over the next several quarters.

Iterum Therapeutics Business Overview & Revenue Model

Company Description

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment o...

Read more

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment o...

How the Company Makes Money

Iterum Therapeutics makes money through the development and potential commercialization of its primary product candidate, sulopenem. The company's revenue model is expected to include income from the sale of sulopenem upon receiving regulatory app...

Read more

Iterum Therapeutics makes money through the development and potential commercialization of its primary product candidate, sulopenem. The company's revenue model is expected to include income from the sale of sulopenem upon receiving regulatory app...

Iterum Therapeutics Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	390.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-668.00K	-254.00K	-1.75M	-1.80M	-2.10M	-161.00K
EBITDA	-23.07M	-21.73M	-34.58M	-39.97M	-83.20M	-36.01M
Net Income	-26.96M	-24.77M	-38.37M	-44.43M	-91.56M	-52.01M
Balance Sheet
Total Assets	32.50M	44.59M	26.26M	66.83M	91.51M	32.79M
Cash, Cash Equivalents and Short-Term Investments	11.00M	24.13M	23.93M	60.80M	81.34M	14.57M
Total Debt	33.73M	45.53M	18.96M	30.10M	30.43M	48.08M
Total Liabilities	39.88M	48.68M	32.66M	38.83M	41.27M	83.35M
Stockholders Equity	-7.38M	-4.08M	-6.40M	28.00M	50.23M	-50.56M
Cash Flow
Free Cash Flow	-19.93M	-26.77M	-39.34M	-18.54M	-15.90M	-54.54M
Operating Cash Flow	-19.91M	-26.77M	-39.33M	-18.47M	-15.84M	-54.53M
Investing Cash Flow	1.09M	18.21M	23.34M	13.96M	-54.59M	-11.00K
Financing Cash Flow	16.27M	26.69M	1.03M	-1.82M	83.13M	64.47M

Iterum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITRMF, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.20, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 26.53 is Positive, neither overbought nor oversold. The STOCH value of 3.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITRMF.

Iterum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLNN	50 Neutral	$75.38M	-2.21	240.83%	―	-49.17%	23.37%
XLO	49 Neutral	$49.15M	―	-311.80%	―	588.40%	61.76%
CAMP	47 Neutral	$237.79M	-2.32	-162.49%	―	―	5.51%
RADX	46 Neutral	$52.37M	-1.28	-105.17%	―	―	―
ITRMF	43 Neutral	$591.75K	-0.85	―	―	―	62.61%
CVM	43 Neutral	$37.13M	-1.93	-226.10%	―	―	48.68%

Iterum Therapeutics Corporate Events